These emerging therapies , Semaglutide , represent a groundbreaking advancement in addressing type 2 diabetes and potentially related conditions . They are categorized as GLP-1 receptor stimulators, indicating these substances to emulate the natural GLP-1 peptide, enhancing metabolic production and lowering hunger . Despite Semaglutide each operate